Lessening Organ Dysfunction With VITamin C (LOVIT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03680274|
Recruitment Status : Completed
First Posted : September 21, 2018
Last Update Posted : April 4, 2022
- Study Details
- Tabular View
- Results Submitted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Sepsis Vitamin C Intensive Care Unit COVID-19 Pandemic Coronavirus||Drug: Vitamin C Other: Control||Phase 3|
Background. The burden of sepsis is increasing worldwide. It is the cause of 8 million global deaths each year. Currently, treatment options are limited to antimicrobials and supportive care such as intravenous fluids, vasopressors, mechanical ventilation, and renal replacement therapy. In the absence of effective therapies specifically targeting the dysregulated immune response, prolonged use of these life-sustaining therapies can be debilitating. A growing body of evidence suggesting that vitamin C, an inexpensive and readily available intervention, is potentially lifesaving in sepsis. Intravenous vitamin C may be the first therapy to mitigate the dysregulated cascade of events that leads to sepsis. If proven effective, vitamin C could be used worldwide and drastically change outcomes in high- and low-income settings alike.
Objectives. To determine whether intravenous vitamin C, compared to placebo, reduces mortality and morbidity in sepsis (induced by bacterial and viral pathogens (as COVID-19)), and compare clinical and biochemical measures of organ dysfunction, and health-related quality of life (HRQoL) at 6 months. To ascertain the volume of distribution, clearance, and plasma concentration over a course of 96 hours of intravenous vitamin C 50 mg/kg of weight every 6 hours or matching placebo (pharmacokinetic (PK) substudy).
Methods. Patients will be randomly assigned to vitamin C (intravenous, 50 mg/kg every 6h) or placebo (0.9% NaCl or dextrose 5% in water) for 96 hours. Study personnel at the clinical sites will document the composite of death or persistent organ dysfunction at day 28. Daily assessments will occur for organ function, on days 1, 3, 7 for inflammation, infection, and endothelial injury biomarkers, at baseline for vitamin C level, and at 6 months for mortality and HRQoL. The LOVIT Trial will be conducted in adult general Canadian and international intensive care units. For the PK substudy: Blood samples will be drawn around the 8th dose at time 0 and then after administration at times 1h, 2h, 4h and 6h (the 6h level will be immediately prior to the next dose). The PK substudy will be conducted with 100 participants in 3 of the 25 participating centers.
Relevance. In the context of increasing off-label use of vitamin C for sepsis and ongoing trials of vitamin C bundled with other pharmacological interventions, the LOVIT Trial will constitute a rigorous assessment of the effect of vitamin C monotherapy on patient-important outcomes.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||872 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Lessening Organ Dysfunction With VITamin C (LOVIT)|
|Actual Study Start Date :||November 8, 2018|
|Actual Primary Completion Date :||August 15, 2021|
|Actual Study Completion Date :||January 24, 2022|
Experimental: Vitamin C
Vitamin C: 50 mg/kg every 6 hours for 96 hours.
Drug: Vitamin C
Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
Other Name: Ascorbic acid
Placebo Comparator: Control
Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
- Number of deceased participants or with persistent organ dysfunction [ Time Frame: Both assessed at 28 days ]Defined as death or dependency on mechanical ventilation, renal replacement, or vasopressors
- Number of participants with persistent organ dysfunction-free days in intensive care unit [ Time Frame: Up to day 28 ]Persistent organ dysfunction-free days in intensive care unit
- Number of participants deceased at 6 months [ Time Frame: 6 months ]Mortality at 6 months
- Score of health related quality of life in 6-month survivors [ Time Frame: 6 months ]
Assessed by the questionnaire EuroQol-5D (EQ-5D-5L). The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'.
- Global tissue dysoxia [ Time Frame: Days 1, 3, 7 ]Assessed by serum lactate concentration
- Organ function (including renal function) [ Time Frame: Days 1, 2, 3, 4, 7, 10, 14, 28 ]Assessed by the Sequential Organ Failure Assessment (SOFA) score. Used to track a person's status during the stay in an intensive care unit to determine the extent of a person's organ function or rate of failure. The score is based on 6 different sub-scores, one each for the respiratory (PaO2/FiO2 mmHg), cardiovascular (mean arterial pressure OR administration of vasopressors required), hepatic (liver bilirubin (mg/dl) [μmol/L]), coagulation (platelets×103/µl), renal (kidneys creatinine (mg/dl) [μmol/L] (or urine output)) and neurological (Glasgow coma scale). The sub-score of each system ranges from 0 (best) to +4 (worst).
- Rate of inflammation [ Time Frame: Days 1, 3, 7 ]Assessed by interleukin-1 beta (IL-1ß), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP).
- Rate of infection [ Time Frame: Days 1, 3, 7 ]Assessed by procalcitonin (PCT)
- Rate of endothelial injury [ Time Frame: Days 1, 3, 7 ]Assessed by thrombomodulin (TM) and angiopoietin-2 (ANG-2)
- Occurrence of stage 3 acute kidney injury [ Time Frame: Up to day 28 ]Assessed by KDIGO (Kidney Disease: Improving Global Outcomes) criteria
- Acute hemolysis [ Time Frame: Up to day 28 ]
- clinician judgment of hemolysis, as recorded in the chart, OR
hemoglobin drop of at least 25 g/L within 24 hours of a dose of investigational product PLUS 2 of the following:
- reticulocyte count >2 times upper limit of normal at clinical site lab;
- haptoglobin < lower limit of normal at clinical site lab;
- indirect (unconjugated) bilirubin >2 times upper limit of normal at clinical site lab;
- Lactate dehydrogenase (LDH) >2 times upper limit of normal at clinical site lab.
- hemoglobin < 75 g/L AND at least 2 of the above criteria AND requires 2 units of packed red blood cells
- Hypoglycemia [ Time Frame: During the time participants receive the 16 doses of the investigational product and the 7 days following the last dose ]Core lab-validated glucose level of less than 3.8 mmol/L
- Vitamin C volume of distribution [ Time Frame: 8th dose of vitamin C at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy) ]Assessed by chromatography-tandem mass spectrometry
- Vitamin C clearance [ Time Frame: 8th dose of vitamin C at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy) ]Assessed by chromatography-tandem mass spectrometry
- Vitamin C plasma concentration [ Time Frame: 8th dose of vitamin C at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy) ]Assessed by chromatography-tandem mass spectrometry
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Admitted to the intensive care unit with proven or suspected infection as the main diagnosis;
- Currently treated with a continuous IV infusion of vasopressors (norepinephrine, epinephrine, vasopressin, dopamine, phenylephrine).
- > 24 hours of intensive care unit admission;
- Known Glucose-6-phosphate dehydrogenase (G6PD) deficiency;
- Known allergy to vitamin C;
- Known kidney stones within the past 1 year;
- Received any intravenous vitamin C during this hospitalization unless incorporated in parenteral nutrition;
- Expected death or withdrawal of life-sustaining treatments within 48 hours;
- Previously enrolled in this study;
- Previously enrolled in a trial with which co-enrolment is not allowed.
The LOVIT trial has broad eligibility criteria and includes patients with a primary diagnosis of sepsis of any cause (including sepsis caused by viral pathogens as COVID-19).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03680274
|Research Center of the CHUS|
|Sherbrooke, Quebec, Canada, J1H 5N4|
|Principal Investigator:||François Lamontagne, MD FRCPC MSc||Université de Sherbrooke and CIUSSS de l'Estrie - CHUS|
|Principal Investigator:||Neill Adhikari, MDCM FRCPC MSc||Sunnybrook Health Sciences Centre, University of Toronto|
Documents provided by François Lamontagne, Université de Sherbrooke:
|Responsible Party:||François Lamontagne, Doctor, professor and researcher, Université de Sherbrooke|
|Other Study ID Numbers:||
|First Posted:||September 21, 2018 Key Record Dates|
|Last Update Posted:||April 4, 2022|
|Last Verified:||March 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||De-identified individual participant data collected during the LOVIT trial will be shared with researchers who provide a detailed and methodologically sound proposal, with specific aims. Data sharing will be for the purposes of medical research, with specific data elements provided to answer the research questions in the proposal, and under the auspices of the consent under which the data were originally gathered.|
Statistical Analysis Plan (SAP)
|Time Frame:||Data availability will commence after the publication of the primary and secondary analyses, with no anticipated end date.|
|Access Criteria:||Qualified researchers will need to sign a data sharing and access agreement and will need to confirm that data will only be used for the agreed upon purpose for which data access was granted. The decision to grant access will be made by the trial co-principal investigators, with involvement of the trial steering committee as needed. Proposals to access LOVIT data should be directed to the trial co-principal investigators via email: email@example.com and firstname.lastname@example.org. Costs of preparing and providing partial datasets will be charged to requesting investigators.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
RNA Virus Infections
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action